CareDx Q2 revenue $132M (+52% YoY); raises FY2026 revenue guidance to $490M-$500M

CareDx, Inc.

Q2 revenue $132M (+52% YoY); Testing Services revenue $100M (+61% YoY) on ~58,000 tests.
GAAP net income $111M (incl. $113M gain on Lab Products sale) vs loss $9M YoY; non-GAAP EPS $0.37.
Adjusted EBITDA $25M vs $5M YoY; raised FY2026 revenue guidance to $490M-$500M (from $447M-$465M).
Raised FY2026 adjusted EBITDA guidance to $66M-$78M (from $43M-$57M).
Closed Lab Products divestiture to Eurobio Scientific and acquired Naveris; CMS finalized coverage for AlloSure/AlloMap.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.